TMCnet News
Pontine Glioma (DIPG) Drug Development Pipeline Study, H1 2018 - ResearchAndMarkets.comThe "Pontine Glioma (DIPG): Drug Development Pipeline Study, H1 2018" report has been added to ResearchAndMarkets.com's offering. The most comprehensive pipeline review Diffuse Intrinsic Pontine Glioma (DIPG) - Drug Development Pipeline Study provides in-depth analysis and update information on Diffuse Intrinsic Pontine Glioma (DIPG) pipeline drugs. Current status of all the drugs in the Diffuse Intrinsic Pontine Glioma (DIPG) pipeline is provided in the research work. The report provides detailed analysis of Diffuse Intrinsic Pontine Glioma (DIPG) pipeline including companies involved, drugs in different stages of development, drug development details across regions (North America, Europe, Asia Pacific and Rest of the World). Further, the Diffuse Intrinsic Pontine Glioma (DIPG) report identifies aspects important in modifying industry market scenarios, increasing opportunities and list of potential companies that impact the Diffuse Intrinsic Pontine Glioma (DIPG) industry. Excerpts from Diffuse Intrinsic Pontine Glioma (DIPG)- Drug Development Pipeline Study: Pontine Glioma pipeline comprises of 24 drugs under development as of February 2018. Of these, 6 drugs are in Phase 1 and 3 drugs are in phase 1/2. Further, 8 drugs are in Phase 2 while 1 drug is in Phase 2/3 stage. In addition, 6 drugs are in Pre-Clinical Stage. Eight drugs have been granted with Orphan drug designation by FDA/ EMA (News - Alert). 37 companies are developing the pipeline for Pontine Glioma. Of this, all the companies are developing one drug each and the Abbvie/ Seattle Genetics, Inc therapeutic candidate- ABT-414 is in Phase 2/3. DIPG is an aggressive type of malignant glioma, arising from glioma tissue. It occurs around pons (brain stem) and impacts the cranial nerves. It also affects the long-tracks in the brain. Symptoms include doule-vision, unable to close eyelids, dropping a side of the face, difficulties in chewing, speech and walking. The solid tumor type is aggressive and accordingly, symptoms also rapidly develop. As these are observed in the bottom area of the brain, they are tough to be treated. Currently, there is no cure for pontine glioma and any FDA / EMA approved treatment exists. Products Mentioned:
Summary: Pontine Glioma pipeline comprises of 24 drugs under development as of February 2018. Of these, 6 drugs are in Phase 1 and 3 drugs are in phase 1/2. Further, 8 drugs are in Phase 2 while 1 drug is in Phase 2/3 stage. In addition, 6 drugs are in Pre-Clinical Stage. Eight drugs have been granted with Orphan drug designation by FDA/ EMA. 37 companies are developing the pipeline for Pontine Glioma. Of this, all the companies are developing one drug each and the Abbvie/ Seattle Genetics, Inc therapeutic candidate - ABT-414 is in Phase 2/3. Key Topics Covered: 1 List of Figures & Tables 2 Executive Summary 3 Pontine Glioma- Company Wise Pipeline Analysis 4 Pontine Glioma Pipeline Drug Snapshots 5 Recent Developments in Pontine Glioma Pipeline 6 Appendix Companies Mentioned
For more information about this report visit https://www.researchandmarkets.com/research/lhfbzv/pontine_glioma?w=4 View source version on businesswire.com: http://www.businesswire.com/news/home/20180228005678/en/ |
